

**January 2022**

# medical benefit specialty drug update **bulletin**

Specialty Drug Program Updates for UnitedHealthcare Commercial, Community Plan, Medicare Advantage, and Individual & Family Plans

Review the table to determine changes to our specialty medical injectable drug programs.

## UPDATES TO DRUG PROGRAM REQUIREMENTS AND DRUG POLICIES

Drug Name	Effective Date	UnitedHealthcare Commercial	UnitedHealthcare Community Plan	UnitedHealthcare Medicare Advantage	UnitedHealthcare Individual & Family	Treatment Uses	Summary of Changes
<b>Alpha1-Proteinase Inhibitors</b> (Aralast NP™, Glassia®, Prolastin-C®, Zemaira®)	4/1/2022		X			Used to treat congenital alpha <sub>1</sub> -proteinase inhibitor (A <sub>1</sub> -PI) deficiency in patients with clinically evident emphysema	Add a prior authorization requirement for all places of service and a Site of Care review for the outpatient hospital setting
<b>Complement Inhibitors</b> (Soliris®, Ultomiris®)	4/1/2022		X			Used to treat certain hematological conditions	Add a Site of Care review for the outpatient hospital setting
<b>Duchenne Muscular Dystrophy Drugs</b> (Amondys 45™, Exondys 51®, Viltepso®, Vyondys 53™)	4/1/2022		X			Used to treat Duchenne muscular dystrophy (DMD)	Add a Site of Care review for the outpatient hospital setting
<b>Enzyme Deficiency Therapy</b> (Aldurazyme®, Elaprase®, Fabrazyme®, Kanuma®)	4/1/2022		X			Used to treat enzyme deficiency disorders such as Mucopolysaccharidosis, Fabry disease, and Pompe disease	Add a prior authorization requirement for all places of service and a Site of Care review for the outpatient hospital setting



<b>Lumizyme<sup>®</sup>, Mepsevii<sup>™</sup>, Naglazyme<sup>®</sup>, Nexviazyme<sup>™</sup>, Revcovi<sup>™</sup>, Vimizim<sup>®</sup>)</b>							
<b>Immune Globulins (IVIG and SCIG)</b>	4/1/2022		X			Used to treat immune deficiencies, autoimmune diseases, and neuroimmunological disorders	Add a Site of Care review for the outpatient hospital setting

Upon prior authorization renewal, the updated policy will apply. UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member's eligibility changes. You don't need to submit a new notification/prior authorization request for members who already have an authorization for these medications on the effective date noted above.

Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230 -RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required. This exception does not apply to Medicaid and Medicare.